Selenium Shields the Liver: Trace Element Preserves Bile Pump and Blocks Cholestatic Damage in Rats

A trace element found in Brazil nuts, seafood, and whole grains may hold the key to protecting one of the liver’s most vulnerable molecular machines. In a study published in Molecular Biology Reports, a research team from Atatürk University in Türkiye reports that pretreatment with selenium substantially reduces liver injury in a rat model of cholestasis, the painful and potentially life-threatening condition in which bile flow is obstructed and toxic bile acids accumulate inside liver cells. The work, led by İsmail Bolat and colleagues, offers one of the most detailed mechanistic pictures to date of how this essential micronutrient defends hepatic tissue, and it arrives with a strikingly clear dose-dependent message: at the higher dose tested, selenium protected nearly every measurable parameter of liver health, while at half that dose its benefits were largely inconsistent and statistically fragile.

Cholestasis arises when the delicate plumbing of the liver fails. Bile, a detergent-like fluid produced by hepatocytes to carry away cholesterol, toxins, and metabolic waste, must be exported through a series of specialized transporter proteins embedded in the canalicular membrane of liver cells. When that export system breaks down, bile acids back up inside hepatocytes, where their detergent properties become a weapon against the very cells that produce them. The result is oxidative stress, inflammatory signaling, programmed cell death, and eventually fibrosis. Among the transporters involved, the bile salt export pump, known as BSEP, occupies a central position. It is the primary efflux pump for conjugated bile acids, and its dysfunction is widely regarded as a key initiating event in cholestatic liver damage, whether the cause is a genetic mutation, a drug side effect, or a chemical insult.

To model this injury experimentally, the researchers turned to alpha-naphthyl isothiocyanate, or ANIT, a compound long used to induce intrahepatic cholestasis in laboratory animals. ANIT damages the biliary epithelium and disrupts canalicular transport, producing a cascade of biochemical and histological changes that closely mirror human cholestatic disease. Sixty male Sprague Dawley rats were randomly assigned to five experimental groups: a healthy control group, a group receiving ANIT alone, two groups pretreated with selenium at doses of 0.5 and 1 milligram per kilogram of body weight before ANIT exposure, and a group receiving selenium alone to assess the element’s intrinsic safety profile at these doses.

The damage inflicted by ANIT was comprehensive. The researchers documented marked suppression of BSEP, along with two other critical transporters, MRP2 and NTCP, which together coordinate the import and export of bile acids and their metabolites across hepatocyte membranes. Simultaneously, the expression of genes governing bile acid synthesis and detoxification, including CYP7A1, UGT1A1, and the nuclear receptor FXR that orchestrates much of bile acid homeostasis, was thrown into disarray. These molecular disruptions translated into measurable clinical harm: serum markers of cholestasis and liver injury climbed, oxidative stress intensified, inflammatory signaling pathways were activated, and hepatocytes underwent increased apoptosis. Under the microscope, liver tissue showed pronounced histopathological injury and early fibrotic changes, confirming that the model had faithfully reproduced the destructive arc of cholestatic disease.

Selenium pretreatment changed that picture dramatically, but only at the higher dose. At 1 milligram per kilogram, the element significantly attenuated ANIT-induced damage across nearly all biochemical, molecular, and histopathological endpoints examined. Bile acid transporter expression was preserved, the balance of bile acid synthesis and detoxification was rebalanced, and the downstream consequences of transporter failure, including oxidative damage, inflammation, and cell death, were substantially blunted. By contrast, the lower dose of 0.5 milligrams per kilogram produced only partial improvements, and for several key parameters, including serum ALT, AST, GGT, and bilirubin levels as well as oxidative and inflammatory markers, the differences relative to the ANIT-only group did not reach statistical significance. This dose-dependence is a critical finding, suggesting that selenium’s protective window in this context is narrower than a simple more-is-better assumption might imply.

Delving into the signaling mechanisms, the team found that the protective effect was accompanied by activation of the NRF2/HO-1 axis, one of the cell’s master antioxidant defense systems, and by stimulation of Sirt1, a nutrient-sensing deacetylase with well-established roles in cellular stress resistance and metabolic regulation. At the same time, selenium suppressed inflammatory signaling mediated by TLR4 and the transcription factor NF-κB, a pathway that ANIT exposure had strongly activated. Perhaps most intriguingly, the researchers observed reactivation of PI3K/AKT/mTOR-dependent pro-survival signaling, suggesting that selenium did not merely mop up reactive oxygen species but actively shifted hepatocytes from a death-oriented to a survival-oriented signaling state. Together, these pathways form a coherent mechanistic narrative in which selenium stabilizes the liver’s bile acid export machinery while simultaneously fortifying its defenses against the oxidative, inflammatory, and apoptotic fallout of cholestatic stress.

The study also incorporated complementary computational analyses that provided structural support for the biological findings. Molecular docking experiments indicated that ANIT forms stable interactions within the inhibitory binding pocket of BSEP, consistent with the idea that the chemical directly interferes with the pump’s function. This structural insight is significant because BSEP inhibition has become a major concern in pharmaceutical development; drug candidates that block the pump are frequently flagged for cholestatic risk, and regulatory agencies and the International Transporter Consortium have emphasized BSEP inhibition testing as a tool for predicting liver injury liability. By anchoring the ANIT model to a structurally plausible mechanism of BSEP interference, the study strengthens the relevance of the selenium protection data to broader questions of drug-induced cholestasis.

Selenium itself is a fascinating and double-edged nutrient. As an essential trace element, it is incorporated into selenoproteins, including the glutathione peroxidases and thioredoxin reductases that form the biochemical backbone of antioxidant defense. Prior research has documented protective effects of selenium against oxidative injury in the kidney, the nervous system, and the liver in various toxicological models, and recent work has linked dietary selenium to amelioration of fatty liver disease through the KEAP1/NRF2 pathway. Yet the element also has a well-defined toxic threshold. The European Food Safety Authority has established a tolerable upper intake level for selenium, and excess intake can itself produce oxidative stress and selenosis. The dose-dependence observed in the current study, in which half the effective dose failed to confer significant protection, underscores that selenium biology is not a simple linear relationship between intake and benefit.

The authors are careful to frame their findings as evidence for a prophylactic rather than a therapeutic role. In the experimental design, selenium was administered before ANIT exposure, meaning the element was present in liver tissue before the cholestatic insult began. This pretreatment strategy allowed selenium to prime antioxidant defenses and stabilize transporter expression ahead of injury, but it does not demonstrate that selenium could reverse established cholestasis. For patients already suffering from cholestatic liver disease, whether from biliary obstruction, drug toxicity, or autoimmune conditions, the study does not yet provide a basis for selenium as a treatment. What it does provide is a proof of principle that maintaining hepatic redox homeostasis and BSEP expression before an insult can dramatically reduce the severity of the resulting injury.

The implications extend in several directions. For clinicians and nutrition scientists, the work adds hepatobiliary protection to the growing list of selenium-dependent health benefits, while reinforcing the importance of adequate but not excessive selenium status. For toxicologists and drug developers, the detailed mapping of the BSEP-FXR-centered protective network offers a mechanistic template for evaluating candidate cholestasis-preventing compounds. And for basic researchers, the study highlights the intricate interplay between bile acid transport, redox signaling, inflammatory pathways, and cell survival machinery that determines whether a stressed liver recovers or spirals into fibrosis. As cholestatic liver diseases continue to impose a substantial clinical burden worldwide, the humble trace element that helps glutathione peroxidase neutralize peroxides may prove to be an unexpectedly powerful ally, provided the dose, the timing, and the therapeutic window are respected with the precision this new research demands.

Subject of Research: Selenium pretreatment and protection against ANIT-induced cholestatic liver injury via BSEP preservation and redox homeostasis

Article Title: Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis

Article References: Bolat, İ., Özdemir, S., Çomakli, S., Sağlam, Y. S., Tekin, S., Çinar, B., Bolat, M., Orhan, B., Sağsöz, M. E., & Okkay, U. (2026). Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis. Molecular Biology Reports, 53(1), Article 1658. https://doi.org/10.1007/s11033-026-12849-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12849-w

Keywords: selenium, cholestasis, BSEP, ANIT, liver injury, oxidative stress, FXR, NRF2, bile acid transporters, NF-kB, hepatoprotection, rats